Altered B:9-23 insulin, when administered intranasally with cholera toxin adjuvant, suppresses the expression of insulin autoantibodies and prevents diabetes

Journal of Immunology

Volumn 179, Issue 4, 2007, Pages 2082-2088

  Kobayashi, Masakazu ^a,c   Abiru, Norio ^a   Arakawa, Takeshi ^b   Fukushima, Keiko ^a   Zhou, Hongbo ^a   Kawasaki, Eiji ^a   Yamasaki, Hironori ^a   Liu, Edwin ^c   Miao, Dongmei ^c   Wong, F Susan ^d   Eisenbarth, George S ^c   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c UNIVERSITY OF COLORADO DENVER   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLERA TOXIN; INSULIN AUTOANTIBODY; INSULIN B9 23; INSULIN DERIVATIVE; UNCLASSIFIED DRUG; AUTOANTIGEN; EPITOPE; IMMUNOLOGICAL ADJUVANT; INSULIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; CD4+ T LYMPHOCYTE; DRUG EFFECT; GENE EXPRESSION REGULATION; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; INTRANASAL DRUG ADMINISTRATION; NONOBESE DIABETIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CHOLERA TOXIN; DIABETES MELLITUS, TYPE 1; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION REGULATION; HYPERGLYCEMIA; IMMUNE TOLERANCE; INSULIN; MICE; MICE, INBRED NOD;

EID: 34848817986     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.4.2082     Document Type: Article

References (28)

1. Martinez, N. R., P. Augstein, A. K. Moustakas, G. K. Papadopoulos, S. Gregori, L. Adorini, D. C. Jackson, and L. C. Harrison. 2003. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J. Clin. Invest. 111: 1365-1371.
2. Moriyama, H., N. Abiru, J. Paronen, K. Sikora, E. Liu, D. Miao, D. Devendra, J. Beilke, R. Gianani, R. G. Gill, and G. S. Eisenbarth. 2003. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc. Natl. Acad. Sci. USA 100: 10376-10381.
3. Nakayama, M., N. Abiru, H. Moriyama, N. Babaya, E. Liu, D. Miao, L. Yu, D. R. Wegmann, J. C. Hutton, J. F. Elliott, and G. S. Eisenbarth. 2005. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435: 220-223.
4. Daniel, D., and D. R. Wegmann. 1996. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA 93: 956-960.
5. Abiru, N., D. Wegmann, E. Kawasaki, P. Gottlieb, E. Simone, and G. S. Eisenbarth. 2000. Dual overlapping peptides recognized by insulin peptide B:9-23 reactive T cell receptor AV13S3 T cell clones of the NOD mouse. J. Autoimmun. 14: 231-237.
6. Wong, F. S., J. Karttunen, C. Dumont, L. Wen, I. Visintin, I. M. Pilip, N. Shastri, E. G. Pamer, and C. A. Janeway, Jr. 1999. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat. Med. 5: 1026-1031.
7. Wong, F. S., A. K. Moustakas, L. Wen, G. K. Papadopoulos, and C. A. Janeway, Jr. 2002. Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA 99: 5551-5556.
8. Alleva, D. G., A. Gaur, L. Jin, D. Wegmann, P. A. Gottlieb, A. Pahuja, E. B. Johnson, T. Motheral, A. Putnam, P. D. Crowe, et al. 2002. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 51: 2126-2134.
9. Abiru, N., A. K. Maniatis, L. Yu, D. Miao, H. Moriyama, D. Wegmann, and G. S. Eisenbarth. 2001. Peptide and MHC-specific breaking of humoral tolerance to native insulin with the B:9-23 peptide in diabetes-prone and normal mice. Diabetes 50: 1274-1281.
10. Arakawa, T., T. Tsuboi, A. Kishimoto, J. Sattabongkot, N. Suwanabun, T. Rungruang, Y. Matsumoto, N. Tsuji, H. Hisaeda, A. Stowers, et al. 2003. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 21: 3143-3148.
11. Liu, E., H. Moriyama, N. Abiru, D. Miao, L. Yu, R. M. Taylor, F. D. Finkelman, and G. S. Eisenbarth. 2002. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J. Clin. Invest. 110: 1021-1027.
12. Yu, L., D. T. Robles, N. Abiru, P. Kaur, M. Rewers, K. Kelemen, and G. S. Eisenbarth. 2000. Early expression of anti-insulin autoantibodies of man and the NOD mouse: evidence for early determination of subsequent diabetes. Proc. Natl. Acad. Sci. USA 97: 1701-1706.
13. Abiru, N., L. Yu, D. Miao, A. K. Maniatis, E. Liu, H. Moriyama, and G. S. Eisenbarth. 2001. Transient insulin autoantibody expression independent of development of diabetes: comparison of NOD and NOR strains. J. Autoimmun. 17: 1-6.
14. Liu, E., N. Abiru, H. Moriyama, D. Miao, and G. S. Eisenbarth. 2002. Induction of insulin autoantibodies and protection from diabetes with subcutaneous insulin B:9-23 peptide without adjuvant. Ann. NY Acad. Sci. 958: 224-227.
15. Chen, W., I. Bergerot, J. F. Elliott, L. C. Harrison, N. Abiru, G. S. Eisenbarth, and T. L. Delovitch. 2001. Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J. Immunol. 167: 4926-4935.
16. Kent, S. C., Y. Chen, L. Bregoli, S. M. Clemmings, N. S. Kenyon, C. Ricordi, B. J. Hering, and D. A. Hafler. 2005. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435: 224-228.
17. Alleva, D. G., P. D. Crowe, L. Jin, W. W. Kwok, N. Ling, M. Gottschalk, P. J. Conlon, P. A. Gottlieb, A. L. Putnam, and A. Gaur. 2001. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin. Invest. 107: 173-180.
18. Daniel, D., R. G. Gill, N. Schloot, and D. Wegmann. 1995. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J. Immunol. 25: 1056-1062.
19. Wegmann, D. R., M. Norbury-Glaser, and D. Daniel. 1994. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur. J. Immunol. 24: 1853-1857.
20. Metzler, B., and D. C. Wraith. 1993. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 5: 1159-1165.
21. von Herrath, M. G., and L. C. Harrison. 2003. Antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol. 3: 223-232.
22. De Magistris, M. T., J. Alexander, M. Coggeshall, A. Altman, F. C. Gaeta, H. M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68: 625-634.
23. Basu, D., C. B. Williams, and P. M. Allen. 1998. In vivo antagonism of a T cell response by an endogenously expressed ligand. Proc. Natl. Acad. Sci. USA 95: 14332-14336.
24. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363: 156-159.
25. Tsitoura, D. C., W. Holter, A. Cerwenka, C. M. Gelder, and J. R. Lamb. 1996. Induction of anergy in human T helper 0 cells by stimulation with altered T cell antigen receptor ligands. J. Immunol. 156: 2801-2808.
26. Nicholson, L. B., J. M. Greer, R. A. Sobel, M. B. Lees, and V. K. Kuchroo. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3: 397-405.
27. Saito, M., S. Otake, M. Ohmura, M. Hirasawa, K. Takada, J. Mega, I. Takahashi, H. Kiyono, J. R. McGhee, Y. Takeda, and M. Yamamoto. 2001. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant. J. Infect. Dis. 183: 823-826.
28. Yamamoto, M., J. R. McGhee, Y. Hagiwara, S. Otake, and H. Kiyono. 2001. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand. J. Immunol. 53: 211-217.